Cargando…
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784968/ https://www.ncbi.nlm.nih.gov/pubmed/36558997 http://dx.doi.org/10.3390/ph15121546 |
_version_ | 1784857938762924032 |
---|---|
author | Lui, Austin Vanleuven, Jordan Perekopskiy, David Liu, Dewey Xu, Desiree Alzayat, Omar Elgokhy, Taiseer Do, Timothy Gann, Meghan Martin, Ryan Liu, Da-Zhi |
author_facet | Lui, Austin Vanleuven, Jordan Perekopskiy, David Liu, Dewey Xu, Desiree Alzayat, Omar Elgokhy, Taiseer Do, Timothy Gann, Meghan Martin, Ryan Liu, Da-Zhi |
author_sort | Lui, Austin |
collection | PubMed |
description | Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments. |
format | Online Article Text |
id | pubmed-9784968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97849682022-12-24 FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders Lui, Austin Vanleuven, Jordan Perekopskiy, David Liu, Dewey Xu, Desiree Alzayat, Omar Elgokhy, Taiseer Do, Timothy Gann, Meghan Martin, Ryan Liu, Da-Zhi Pharmaceuticals (Basel) Review Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments. MDPI 2022-12-13 /pmc/articles/PMC9784968/ /pubmed/36558997 http://dx.doi.org/10.3390/ph15121546 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lui, Austin Vanleuven, Jordan Perekopskiy, David Liu, Dewey Xu, Desiree Alzayat, Omar Elgokhy, Taiseer Do, Timothy Gann, Meghan Martin, Ryan Liu, Da-Zhi FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title_full | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title_fullStr | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title_full_unstemmed | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title_short | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
title_sort | fda-approved kinase inhibitors in preclinical and clinical trials for neurological disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784968/ https://www.ncbi.nlm.nih.gov/pubmed/36558997 http://dx.doi.org/10.3390/ph15121546 |
work_keys_str_mv | AT luiaustin fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT vanleuvenjordan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT perekopskiydavid fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT liudewey fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT xudesiree fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT alzayatomar fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT elgokhytaiseer fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT dotimothy fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT gannmeghan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT martinryan fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT liudazhi fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders |